BMC Neuroscience Cellular and Molecular Neuroscience
Molecular docking and experimental evaluation of neocuproine in targeting in vitro model of Parkinson’s disease caused by 6-hydroxydopamine
Abstract
Abstract Background 6-Hydroxydopamine (6-OHDA) induces oxidative and cellular stress in SH-SY5Y cells and is widely used as an in vitro model relevant to Parkinson’s disease (PD). This study investigated the effects of neocuproine, a copper chelator, on 6-OHDA-induced cellular injury in SH-SY5Y cells. Results 6-OHDA increased total oxidant status (TOS), malondialdehyde (MDA), caspase-3 (CASP3), LDH release, and IL-1β and TNF-α levels, while reducing cell viability and total antioxidant capacity (TAC). Neocuproine treatment reduced LDH, TOS, MDA, CASP3, IL-1β, and TNF-α levels and increased TAC compared with the 6-OHDA group. The response was non-linear, with several effects being more pronounced at intermediate concentrations. Neocuproine also reduced α-synuclein immunofluorescence and increased TH immunofluorescence at selected concentrations. Molecular docking provided exploratory information on the predicted interactions of neocuproine with selected PD-related proteins. Conclusion Neocuproine was associated with reduced oxidative stress, cellular injury, and inflammatory marker levels in the 6-OHDA-induced SH-SY5Y model. These findings support further investigation of neocuproine in experimental PD models. However, the absence of a standard comparator and complementary protein-level validation limits conclusions regarding its mechanism and therapeutic applicability.